Contact Us
Drug Search Results
More Filters [+]

Oritavancin

Alternative Names: oritavancin, kimyrsa, orbactiv
Latest Update: 2024-07-09
Latest Update Note: Clinical Trial Update

Product Description

Oritavancin is a lipoglycopeptide with bactericidal activity against gram-positive bacteria.  (Sourced from: https://www.nejm.org/doi/full/10.1056/nejmoa1310422)

Mechanisms of Action: Cell Wall Inhibitor

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Italy | Jordan | Latvia | Lithuania | Poland | Portugal | Saudi Arabia | Slovakia | Spain | Sweden | Switzerland | United Kingdom | United States

Approved Indications: Gram-Positive Bacterial Infections | Gram-Positive Bacterial Infections

Known Adverse Events: Headache | Pruritus | Abscess | Chills | Diarrhea

Company: Melinta
Company Location: MORRISTOWN NJ 07963
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Oritavancin

Countries in Clinic: Bulgaria, Greece, Latvia, Lithuania, Poland, Portugal, Romania, Spain, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Skin Diseases, Bacterial

Phase 1: Other

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2022-001297-63

P2

Active, not recruiting

Unknown

2026-04-05

ML-ORI-201

P2

Recruiting

Skin Diseases, Bacterial

2025-06-15

24%
ORKIDS

P1

Completed

Other

2021-05-17

Recent News Events

Date

Type

Title

05/23/2024

News Article

 Melinta Therapeutics Announces Publication of the Outcomes by Candida Species from the ReSTORE Phase 3 trial and Recently Approved Rezafungin CLSI Breakpoints for Candida glabrata and Candida auris

02/23/2024

News Article

 Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam

02/20/2024

News Article

 New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection

12/05/2023

News Article

 Melinta Therapeutics & Cidara Therapeutics Announce Publication of Pooled Data from Phase 3 Pivotal ReSTORE Trial & Phase 2 STRIVE Trial of REZZAYO® (rezafungin for injection) for the Treatment of Candidemia & Invasive Candidiasis in The Lancet ID

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions